ObsEva SA (NASDAQ:OBSV) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.

Brokerages have set a 1-year consensus target price of $21.00 for the company and are forecasting that the company will post ($0.54) earnings per share for the current quarter, according to Zacks. Zacks has also assigned ObsEva SA an industry rank of 167 out of 265 based on the ratings given to its competitors.

OBSV has been the subject of a number of recent analyst reports. Jefferies Group LLC initiated coverage on ObsEva SA in a research report on Tuesday, February 21st. They set a “buy” rating and a $21.00 target price for the company. Credit Suisse Group initiated coverage on ObsEva SA in a research report on Tuesday, February 21st. They set an “outperform” rating and a $27.00 target price for the company. Leerink Swann initiated coverage on ObsEva SA in a research report on Tuesday, February 21st. They set an “outperform” rating and a $21.00 target price for the company. Finally, Zacks Investment Research upgraded ObsEva SA from a “sell” rating to a “hold” rating in a research report on Tuesday, May 30th.

Institutional investors have recently bought and sold shares of the company. UBS Oconnor LLC acquired a new position in ObsEva SA during the first quarter worth approximately $1,017,000. Baker Avenue Asset Management LP acquired a new position in ObsEva SA during the first quarter worth approximately $104,000. Paloma Partners Management Co acquired a new position in ObsEva SA during the first quarter worth approximately $131,000. Iguana Healthcare Management LLC acquired a new position in ObsEva SA during the first quarter worth approximately $260,000. Finally, Nexthera Capital LP acquired a new position in ObsEva SA during the first quarter worth approximately $521,000. 49.24% of the stock is owned by institutional investors.

ObsEva SA (NASDAQ:OBSV) traded down 10.81% during mid-day trading on Wednesday, reaching $5.98. 59,098 shares of the company’s stock traded hands. The stock’s market capitalization is $159.21 million. ObsEva SA has a 12 month low of $5.70 and a 12 month high of $14.69. The firm’s 50-day moving average price is $7.62 and its 200 day moving average price is $9.91.

ObsEva SA (NASDAQ:OBSV) last released its quarterly earnings results on Thursday, May 18th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by $0.17. Equities research analysts predict that ObsEva SA will post ($2.11) EPS for the current year.

WARNING: This piece was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/06/14/obseva-sa-obsv-given-average-rating-of-strong-buy-by-analysts.html.

ObsEva SA Company Profile

Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.

Get a free copy of the Zacks research report on ObsEva SA (OBSV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ObsEva SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva SA and related companies with MarketBeat.com's FREE daily email newsletter.